Excipia logo

Fully dedicated to Excipient Characterization

Excipients can have an important impact on the pharmaceutical and chemical performance of a drug product formulation. It’s therefore important to identify and control unknown Functionality Related Characteristics (FRCs) of excipient materials in order to achieve safe, robust and stable products.

Complementary to a Certificate of Analysis

Being active for 25 years in formulation development has learned us that the limited information on an excipient Certificate of Analysis often falls short in explaining observed formulation characteristics or in appointing product specific FRCs. So there must be more to it,....

In the past 15 years analytical scientists of Excipia have worked hard to set up unique analytical and physicochemical methods with ingenious sample preparation techniques and successfully filled this knowledge gap for a broad variety of excipients. For some excipients, up to one hundred unique batches of different grades and suppliers were analyzed to compile a knowledge database.

With all this, Excipia can help your company to identify critical FRCs of excipients and combination of excipients in a formulation, or investigate batch to batch variability, select specific excipient batches or set in-house specifications for customized product properties.

Reverse Engineering and Beyond

Our experience in excipient characterization enables us not only
to identify and quantify individual excipients in a drug product (deformulation)
but also to investigate excipient reactivity and reveal hidden excipient properties like :

- the presence of potential reactive impurities or functional groups www.excipia.eu Excipient characterization
- degradation products
- related substances
- molecular weight distributions
- degree of substitution
- substituent distribution
- monomer ratio
- other featured characteristics

Hands-on troubleshooting services and solutions

Excipia offers fast and flexible hands-on solutions and troubleshooting services to pharmaceutical drug companies and excipient manufacturers that are encountering challenges such as:

• • • •
Competitor research and analysis
Deformulation or reverse engineering
Selection of excipient or feedstock
Batch-to-batch product performance variation, e.g. manufacturability, stability, release, etc.
Identifying Functionality Related Characteristics (FRCs) and setting product specific (in-house) specifications
Implementing a Quality by Design (QbD) approach
Manufacturing process or site changes
• • • •

Feel free to get in touch with our experts to see how we can help you in making your products safe, robust and stable.

Be in control of your product!

Excipient Case Study

VARIABILITY OF EXCIPIENTS: Xylose in microcrystalline cellulose

Compatibility of excipients in drug products is demonstrated in accelerated and real-time stability programs, but too often batch-to-batch variability of excipients is ignored. Many excipients are derived through processing of natural animal, vegetable or mineral sources. Variability is introduced not only by process technology or process parameters, but also by inadequate specifications of starting materials;
species of crop, different regional and seasonal provenance may contribute to batch-to-batch inconsistency.
Excipia analyzed about 100 Microcrystalline Cellulose (MCC) samples from various manufacturers and grades for properties like molecular weight distribution, chemical composition, purity and chemical reactivity.
We identified, amongst other things, a relation between the content of xylose and the reactive aldehyde furfural in MCC.

Excipia: VARIABILITY OF EXCIPIENTS: Xylose in microcrystalline cellulose

Furfural is a degradation product of pentoses like xylose and often found to unfavorably affect the stability of medicines.

Download full article HERE
www.Excipia.eu Excipient analysis
www.excipia.eu Excipient sample preparation techniques
www.excipia.eu Excipia Excipient characterization
www.Excipia.eu Excipient analysis laboratory

Excipia, a division of Avivia BV

Excipia as dedicated excipient knowledge platform is a division of Avivia BV, a Dutch independent specialized pharmaceutical development company that operates a hybrid business model combining CRO service activities with internal product development programs. The other complementary platforms of Avivia are Pharmaceutical R&D, Analytical R&D, and Biorelevant Dissolution Testing. For more information about Avivia and its pharmaceutical development CRO services, please visit the Avivia website.
Transistorweg 5, 6534 AT Nijmegen, The Netherlands